Author(s):
SV Deshmane, PP Chinchole, RM Gaurkhede, MA Channawar, AV Chandewar
Email(s):
subdeshmane@yahoo.co.in
DOI:
Not Available
Address:
SV Deshmane*, PP Chinchole, RM Gaurkhede, MA Channawar and AV Chandewar.
P. Wadhwani College of Pharmacy, Dhamangaon road, Girija Nagar, Yavatmal – 445001 (M.S.)
*Corresponding Author
Published In:
Volume - 2,
Issue - 1,
Year - 2009
ABSTRACT:
The reports dealing with solubility, dissolution issues related to BCS, prompted us to re-examine theoretically the role of the dimensionless solubility/dose ratio in the dissolution and GI absorption kinetics of drugs. In parallel, this study pays attention not only to the theoretical basis for the biopharmaceutics classification of new molecular entities (NMEs), but also for marketed drugs. Early high throughput screening information regarding solubility and permeability should be invaluable to discovery chemists. While savings resulting from application of the BCS to obtain waivers of in vivo bioequivalence studies are notable, they may not represent the most significant benefit from application of the BCS. The BCS was primarily developed for a better understanding of the relationship of drug release (in vivo) from the product and the absorption process. In this respect, the question of the rate-limiting step is of primary relevance. Further, it has been reported that 39% of compounds in development fail because of poor biopharmaceutical properties
Cite this article:
SV Deshmane, PP Chinchole, RM Gaurkhede, MA Channawar, AV Chandewar. The Biopharmaceutics Classification System: A Review. Research J. Pharm. and Tech. 2(1): Jan.-Mar. 2009; Page 8-11
Cite(Electronic):
SV Deshmane, PP Chinchole, RM Gaurkhede, MA Channawar, AV Chandewar. The Biopharmaceutics Classification System: A Review. Research J. Pharm. and Tech. 2(1): Jan.-Mar. 2009; Page 8-11 Available on: https://rjptonline.org/AbstractView.aspx?PID=2009-2-1-60